Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Chesnay-Rocquencourt – page 211

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Chesnay-Rocquencourt at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Progressive supranuclear palsy

Not recruiting

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

Ventricular tachycardia

Not recruiting

Study on the Safety of CRD-4730 for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Biliary tract disorder

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Glioblastoma

Not recruiting

Study on the Safety and Effectiveness of 2-Hydroxyoleic Acid and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Idroxioleic acid
  • Sponsor:Laminar Pharmaceuticals S.A.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Ovarian cancer

Not recruiting

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Primary hyperaldosteronism

Not recruiting

Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pentixafor
  • Sponsor:Assistance Publique Hopitaux De Paris

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pneumococcal polysaccharide serotype 15A conjugated to CRM197
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Osteochondrodysplasia

Not recruiting

Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

  • Pain management in heart attacks
  • Asthma treatment optimization
  • Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

  • Blood cancer therapies
  • Leukemia treatments
  • Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

  • RSV prevention
  • Infant protection studies
  • Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.